Abstract：
BACKGROUND: Financial conflicts of interest (FCOI) of medical professionals and associated organizations with pharmaceutical companies (pharma) might contribute to the use of low value oncological treatments. Value criteria for oncological drug approvals in the Netherlands have recently become more stringent leading to objections by cancer patient advocacy organizations (cPAOs). Considering the importance of cPAOs input in cancer patient care we analyzed whether pharma funding of cPAOs occurs in the Netherlands.
METHODS: The cPAO websites and available annual reports were evaluated for disclosure of pharma funding for the years 2021 and 2022. Also, data from the Dutch Healthcare Transparency Registry (DHTR) were extracted.
RESULTS: Twenty-one of 34 (61.8 %) cPAOs received pharma funding (with 20 registered in the DHTR), and for 13 (29.4 %) cPAOs no reporting of pharma funding could be found. Three of the cPAOs disclosed pharma funding directly on their main website. Online educational material was available from 22 cPAOs on their websites with pharma funding disclosed on the educational material in 5. The total registered amount of pharmaceutical funding was €667,232.00 in 2021 and €536,098.00 in 2022. The median (and interquartile ranges) DHTR registered amount of support per cPAO that received funding in the studied period was €23,799.50 (14,823.75-84,663.30). The most common funding category as defined in the DHTR was project sponsorship.
CONCLUSIONS: Financial support by the pharmaceutical industry is common for Dutch cPAOs. Given the importance of cPAOs and their objective input in the societal debate on the availability of cancer drugs, the potential influence of pharma sponsoring should be critically evaluated.
METHODS: The cPAO websites and available annual reports were evaluated for disclosure of pharma funding for the years 2021 and 2022. Also, data from the Dutch Healthcare Transparency Registry (DHTR) were extracted.
RESULTS: Twenty-one of 34 (61.8 %) cPAOs received pharma funding (with 20 registered in the DHTR), and for 13 (29.4 %) cPAOs no reporting of pharma funding could be found. Three of the cPAOs disclosed pharma funding directly on their main website. Online educational material was available from 22 cPAOs on their websites with pharma funding disclosed on the educational material in 5. The total registered amount of pharmaceutical funding was €667,232.00 in 2021 and €536,098.00 in 2022. The median (and interquartile ranges) DHTR registered amount of support per cPAO that received funding in the studied period was €23,799.50 (14,823.75-84,663.30). The most common funding category as defined in the DHTR was project sponsorship.
CONCLUSIONS: Financial support by the pharmaceutical industry is common for Dutch cPAOs. Given the importance of cPAOs and their objective input in the societal debate on the availability of cancer drugs, the potential influence of pharma sponsoring should be critically evaluated.
摘要：
背景：医疗专业人员和相关组织与制药公司（pharma）的财务利益冲突（FCOI）可能导致使用低价值的肿瘤治疗。荷兰肿瘤药物批准的价值标准最近变得更加严格，导致癌症患者倡导组织（cPAO）的反对。考虑到cPAOs投入在癌症患者护理中的重要性，我们分析了cPAOs的药物资助是否发生在荷兰。
方法：评估了cPAO网站和可用的年度报告，以披露2021年和2022年的药品资金。此外，数据来自荷兰医疗保健透明度登记处（DHTR）。
结果：34个cPAO中有21个（61.8％）获得了制药资助（其中20个在DHTR注册），对于13名(29.4%)cPAO，找不到制药资金的报告。三名cPAO直接在其主要网站上披露了制药资金。在线教育材料可从22个cPAO的网站上获得，药品资金在5的教育材料中披露。2021年医药资金的注册总额为667,232.00欧元，2022年为536,098.00欧元。在研究期间获得资金的每个cPAO的DHTR注册支持金额的中位数（和四分位数范围）为23,799.50欧元（IQR14,823.75-84,663.30）。DHTR中定义的最常见的资金类别是项目赞助。
结论：制药行业的财政支持对于荷兰cPAO来说很常见。鉴于cPAO的重要性及其在癌症药物可用性的社会辩论中的客观投入，应严格评估制药赞助的潜在影响.
方法：评估了cPAO网站和可用的年度报告，以披露2021年和2022年的药品资金。此外，数据来自荷兰医疗保健透明度登记处（DHTR）。
结果：34个cPAO中有21个（61.8％）获得了制药资助（其中20个在DHTR注册），对于13名(29.4%)cPAO，找不到制药资金的报告。三名cPAO直接在其主要网站上披露了制药资金。在线教育材料可从22个cPAO的网站上获得，药品资金在5的教育材料中披露。2021年医药资金的注册总额为667,232.00欧元，2022年为536,098.00欧元。在研究期间获得资金的每个cPAO的DHTR注册支持金额的中位数（和四分位数范围）为23,799.50欧元（IQR14,823.75-84,663.30）。DHTR中定义的最常见的资金类别是项目赞助。
结论：制药行业的财政支持对于荷兰cPAO来说很常见。鉴于cPAO的重要性及其在癌症药物可用性的社会辩论中的客观投入，应严格评估制药赞助的潜在影响.
